Phase 2, multicenter, single-arm study of eribulin mesylate with trastuzumab as first-line therapy for locally recurrent or metastatic HER2-positive breast cancer

Clinical Breast Cancer

Volumn 14, Issue 6, 2014, Pages 405-412

  Wilks, Sharon ^a   Puhalla, Shannon ^b   O'Shaughnessy, Joyce ^c   Schwartzberg, Lee ^d   Berrak, Erhan ^e   Song, James ^e   Cox, David ^e   Vahdat, Linda ^f  

^a Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^d West Clinic Memphis   (United States)

^e EISAI INC   (United States)

^f WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Advanced breast cancer; Breast neoplasm; Chemotherapy; Nontaxane microtubule dynamics inhibitor; Oncology

Indexed keywords

ERIBULIN; TRASTUZUMAB; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; FURAN DERIVATIVE; KETONE; MONOCLONAL ANTIBODY;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BACKACHE; BONE METASTASIS; BONE PAIN; BREAST CANCER; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CHILL; CONSTIPATION; CONTROLLED STUDY; DECREASED APPETITE; DEPRESSION; DIARRHEA; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DYSGEUSIA; DYSPEPSIA; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HUMAN; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 POSITIVE BREAST CANCER; HYPERGLYCEMIA; INSOMNIA; LEUKOPENIA; LIVER METASTASIS; LUNG METASTASIS; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUSCLE SPASM; NAUSEA; OROPHARYNX PAIN; OUTCOME ASSESSMENT; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; SINGLE BLIND PROCEDURE; STOMATITIS; TREATMENT DURATION; URINARY TRACT INFECTION; VOMITING; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CLINICAL TRIAL; FOLLOW UP; METABOLISM; METASTASIS; MIDDLE AGED; MORTALITY; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; PROGNOSIS; SECONDARY; SURVIVAL RATE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; FEMALE; FOLLOW-UP STUDIES; FURANS; HUMANS; KETONES; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, ERBB-2; SURVIVAL RATE;

EID: 84911405837     PISSN: 15268209     EISSN: 19380666     Source Type: Journal    
DOI: 10.1016/j.clbc.2014.04.004     Document Type: Article

References (47)

1. National Cancer Institute. Surveillance, Epidemiology, and End Results Program. SEER Stat Fact Sheets: Breast. Available at: http://seer.cancer.gov/statfacts/html/breast.html. Accessed January 14, 2014.
2. American Cancer Society. Breast Cancer Facts and Figures 2013-2014. Available at: http://www.cancer.org/acs/groups/content/@research/documents/document/acspc-042725.pdf. Accessed February 10, 2014.
3. J.S. Ross, E.A. Slodkowska, W.F. Symmans, L. Pusztai, P.M. Ravdin, and G.N. Hortobagyi The HER-2 receptor and breast cancer: ten years of targeted anti-HER2 therapy and personalized medicine Oncologist 14 2009 320 368
4. M.J. Lund, E.N. Butler, and B.Y. Hair Age/race differences in HER2 testing and in incidence rates for breast cancer triple subtypes: a population-based study and first report Cancer 116 2010 2549 2559
5. G. Valabrega, F. Montemurro, and M. Aglietta Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer Ann Oncol 18 2007 977 984
6. National Comprehensive Cancer Network NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Breast Cancer 2014 National Comprehensive Cancer Network Fort Washington, PA
7. V. Heinemann, D. Di Gioia, and U. Vehling-Kaiser A prospective multicenter phase II study of oral and i.v. vinorelbine plus trastuzumab as first-line therapy in HER2-overexpressing metastatic breast cancer Ann Oncol 22 2011 603 608
8. S. Redana, M. Donadio, and F. Nole Trastuzumab with either docetaxel or vinorelbine as first-line treatment for patients with HER2-positive advanced breast cancer: a retrospective comparison BMC Cancer 10 2010 28
9. A.M. Wardley, X. Pivot, and F. Morales-Vasquez Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer J Clin Oncol 28 2010 976 983
10. V. Michalaki, S. Fotiou, S. Gennatas, and C. Gennatas Trastuzumab plus capecitabine and docetaxel as first-line therapy for HER2-positive metastatic breast cancer: phase II results Anticancer Res 30 2010 3051 3054
11. A. Chan, P.F. Conte, and L. Petruzelka Phase II study of a triple combination of oral vinorelbine, capecitabine and trastuzumab as first-line treatment in HER2-positive metastatic breast cancer Anticancer Res 33 2013 2657 2664
12. K. Inoue, K. Nakagami, and M. Mizutani Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group Breast Cancer Res Treat 119 2010 127 136
13. O. Tonyali, M. Benekli, and V. Berk Efficacy and toxicity of trastuzumab and paclitaxel plus capecitabine in the first-line treatment of HER2-positive metastatic breast cancer J Cancer Res Clin Oncol 139 2013 981 986
14. W.W. Tan, J.B. Allred, and M. Salim Phase II interventional study (N0337) of capecitabine in combination with vinorelbine and trastuzumab for first- or second-line treatment of HER2-positive metastatic breast cancer: a North Central Cancer Treatment Group trial Clin Breast Cancer 12 2012 81 86
15. S. Moulder, H. Li, and M. Wang A phase II trial of trastuzumab plus weekly ixabepilone and carboplatin in patients with HER2-positive metastatic breast cancer: an Eastern Cooperative Oncology Group Trial Breast Cancer Res Treat 119 2010 663 671
16. J. Baselga, J. Cortes, and S.B. Kim Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer N Engl J Med 366 2012 109 119
17. D. Slamon, W. Eiermann, and N. Robert Adjuvant trastuzumab in HER2-positive breast cancer N Engl J Med 365 2011 1273 1283
18. M.A. Jordan, K. Kamath, and T. Manna The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth Mol Cancer Ther 4 2005 1086 1095
19. T. Okouneva, O. Azarenko, L. Wilson, B.A. Littlefield, and M.A. Jordan Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase Mol Cancer Ther 7 2008 2003 2011
20. J.A. Smith, L. Wilson, and O. Azarenko Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability Biochemistry 49 2010 1331 1337
21. M.A. Jordan, and K. Kamath How do microtubule-targeted drugs work? An overview Curr Cancer Drug Targets 7 2007 730 742
22. S. Jain, and T. Cigler Eribulin mesylate in the treatment of metastatic breast cancer Biologics 6 2012 21 29
23. J. Cortes, J. O'Shaughnessy, and D. Loesch Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study Lancet 377 2011 914 923
24. Halaven (eribulin mesylate) injection [prescribing information] 2013 Eisai Inc Woodcliff Lake, NJ
25. S.A. Hurvitz, L. Dirix, and J. Kocsis Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer J Clin Oncol 31 2013 1157 1163
26. S. Servitja, M. Ramos, and M. Gil Multicenter, phase II, nonrandomized study of docetaxel plus trastuzumab every 21 days as the primary therapy in metastatic breast cancer overexpressing HER2 Anticancer Drugs 23 2012 239 246
27. M. Andersson, E. Lidbrink, and K. Bjerre Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study J Clin Oncol 29 2011 264 271
28. M. Marty, F. Cognetti, and D. Maraninchi Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group J Clin Oncol 23 2005 4265 4274
29. D. Yamamoto, S. Iwase, K. Kitamura, H. Odagiri, C. Yamamoto, and Y. Nagumo A phase II study of trastuzumab and capecitabine for patients with HER2-overexpressing metastatic breast cancer: Japan Breast Cancer Research Network (JBCRN) 00 Trial Cancer Chemother Pharmacol 61 2008 509 514
30. G. Fountzilas, D. Tsavdaridis, and A. Kalogera-Fountzila Weekly paclitaxel as first-line chemotherapy and trastuzumab in patients with advanced breast cancer. A Hellenic Cooperative Oncology Group phase II study Ann Oncol 12 2001 1545 1551
31. G. Gasparini, M. Gion, and L. Mariani Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with HER2 positive advanced breast cancer Breast Cancer Res Treat 101 2007 355 365
32. N. Robert, B. Leyland-Jones, and L. Asmar Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER2-overexpressing metastatic breast cancer J Clin Oncol 24 2006 2786 2792
33. J.J. Lee, and S.M. Swain Peripheral neuropathy induced by microtubule-stabilizing agents J Clin Oncol 24 2006 1633 1642
34. E.M. Smith Current methods for the assessment and management of taxane-related neuropathy Clin J Oncol Nurs 17 suppl 2013 22 34
35. L.T. Vahdat, E.S. Thomas, and H.H. Roche Ixabepilone-associated peripheral neuropathy: data from across the phase II and III clinical trials Support Care Cancer 20 2012 2661 2668
36. K.M. Wozniak, K. Nomoto, and R.G. Lapidus Comparison of neuropathy-inducing effects of eribulin mesylate, paclitaxel, and ixabepilone in mice Cancer Res 71 2011 3952 3962
37. M.D. Stubblefield, H.J. Burstein, and A.W. Burton NCCN task force report: management of neuropathy in cancer J Natl Compr Cancer Network 7 suppl 5 2009 S1 26
38. National Cancer Institute. Common Terminology Criteria for Adverse Events v3.0. Available at: http://ctep.cancer.gov/protocolDevelopment/electronic-applications/docs/ctcaev3.pdf. Accessed April 8, 2014.
39. J.A. Ajani, S.R. Welch, M.N. Raber, W.S. Fields, and I.H. Krakoff Comprehensive criteria for assessing therapy-induced toxicity Cancer Invest 8 1990 147 159
40. A.B. Miller, B. Hoogstraten, M. Staquet, and A. Winkler Reporting results of cancer treatment Cancer 47 1981 207 214
41. M.M. Oken, R.H. Creech, and D.C. Tormey Toxicity and response criteria of the Eastern Cooperative Oncology Group Am J Clin Oncol 5 1982 649 655
42. C.S. Cleeland, and K.M. Ryan Pain assessment: global use of the Brief Pain Inventory Ann Acad Med Singapore 23 1994 129 138
43. M.B. Tittle, S.C. McMillan, and S. Hagan Validating the brief pain inventory for use with surgical patients with cancer Oncol Nurs Forum 30 2003 325 330
44. B.S. Galer, and M.P. Jensen Development and preliminary validation of a pain measure specific to neuropathic pain: the Neuropathic Pain Scale Neurology 48 1997 332 338
45. M.P. Jensen, M. Friedman, D. Bonzo, and P. Richards The validity of the neuropathic pain scale for assessing diabetic neuropathic pain in a clinical trial Clin J Pain 22 2006 97 103
46. M. Bennett The LANSS Pain Scale: the Leeds assessment of neuropathic symptoms and signs Pain 92 2001 147 157
47. J. Potter, I.J. Higginson, J.W. Scadding, and C. Quigley Identifying neuropathic pain in patients with head and neck cancer: use of the Leeds Assessment of Neuropathic Symptoms and Signs Scale J R Soc Med 96 2003 379 383